Resverlogix Corp RVXCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.03
- Day Range
- $0.04–0.05
- 52-Week Range
- $0.03–0.08
- Bid/Ask
- $0.03 / $0.05
- Market Cap
- $9.87 Mil
- Volume/Avg
- 32,500 / 6,785
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 18
- Website
- https://www.resverlogix.com
Valuation
|
Metric
|
RVXCF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RVXCF
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.05 |
Interest Coverage | −3.71 |
Quick Ratio
RVXCF
Profitability
|
Metric
|
RVXCF
|
|---|---|
Return on Assets (Normalized) | −101.84% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RVXCF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Njrltpfdrc | Jswg | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bpbzbmb | Jjmxhz | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Htztxzy | Dzbgdk | $118.7 Bil | |||
| Moderna Inc
MRNA
| Fszlcls | Qplk | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kfdsvmnc | Dgfqv | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Svytkymf | Yrxh | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Fjlwmpdft | Ydgwt | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kgbsqnjyv | Htcvq | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Pwchpytz | Hzctf | $15.0 Bil | |||
| Incyte Corp
INCY
| Jwkrsswb | Tlvywq | $13.5 Bil |